Alumis Inc. research snapshot
ALMS AI stock analysis currently reads Alumis Inc. as a high-risk, high-potential clinical-stage biopharmaceutical company focused on TYK2 inhibitors for autoimmune diseases. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $28.31, market capitalization was about $3.61 billion, and the key question was whether envudeucitinib clinical data, regulatory progress, and cash management can justify a 346x price-to-sales ratio for a company with negative TTM earnings. This is informational research and not investment advice.
Current price
$28.31
Market cap
$3.61 billion
AI score
42 / 100
Rating
High-risk clinical-stage biotech with strong cash position and promising TYK2 pipeline
Trend status
Strong uptrend from $3.24 52-week low, near all-time highs above $31
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alumis is developing TYK2 inhibitors for autoimmune diseases. Its lead candidate envudeucitinib targets a validated mechanism. Revenue is negligible at $8.4M TTM with -$237.4M net income. | Medium |
| Moat | The moat depends on clinical differentiation of envudeucitinib versus BMS Sotyktu and other TYK2 inhibitors. If envudeucitinib shows superior efficacy or safety, it could carve a significant position in large autoimmune markets. | Low |
| Management | Professional management team with biotech industry experience. Capital allocation includes IPO proceeds and follow-on offerings. Key-person risk exists around clinical development leadership. | Medium-low |
| Financial trend | Revenue is minimal with negative net income of -$237.4M TTM. The company has $522.9M cash providing runway into 2028. Q1 2026 showed R&D expenditure of $71.8M, consistent with clinical-stage biotech burn rates. | Medium |
| Valuation | At the cutoff price, the stock traded at roughly 346x TTM sales and a negative P/E. Price-to-book of 6.37x. Valuation fully prices in successful clinical development and significant commercial potential. | Low |
| Technical trend | ALMS is in a strong uptrend with the stock up over 695% from its 52-week low. Momentum is bullish but extended, with the stock near the all-time highs. | Medium |
| Risk level | Key risks are clinical trial failure, regulatory denial, commercial execution risk, cash burn requiring dilution, intense competition in autoimmune space, and binary-outcome event risk. | Medium |
| AI confidence | Medium confidence for financial data and pipeline milestones. Lower confidence for clinical success probabilities, regulatory timelines, and commercial revenue projections. | Medium data confidence |
| Investment certainty | Low certainty. ALMS offers high upside if envudeucitinib succeeds in Phase 3 and gains approval, but clinical-stage biotech stocks carry binary risk. The current valuation already reflects significant optimism. | Low |
ALMS AI stock forecast
The ALMS AI stock forecast uses scenario ranges around the $28.31 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires positive envudeucitinib Phase 3 data and successful regulatory and commercial path. The base case assumes clinical progress with typical biotech volatility. The bearish case assumes clinical setbacks or pipeline delays.
$50 to $70
More likely if envudeucitinib delivers positive Phase 3 data in psoriasis or SLE, the company establishes a clear differentiation versus Sotyktu, and management maintains strong cash management without dilutive near-term financing.
$20 to $40
More likely if clinical development progresses with typical timelines, the stock trades in line with clinical-stage biotech peers, and investors balance pipeline potential against cash burn and dilution risk.
$8 to $18
More likely if envudeucitinib faces clinical setbacks, safety signals emerge, regulatory delays occur, or significant equity dilution becomes necessary to fund ongoing development.
ALMS AI technical analysis
ALMS AI technical analysis starts from the $28.31 July 10 close used for this July 12 static page. Public technical sources showed the stock in a strong uptrend from its $3.24 52-week low. Biotech stocks often have elevated volatility around clinical data readouts. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $28.31 | Latest verified close used for this page as of the July 12, 2026 data cutoff. Stock has rallied over 695% from the 52-week low. |
| Near support | $24.00 to $26.00 | Support zone around the 20-day moving average area. Pullbacks to this zone could offer entries if the uptrend remains intact. |
| Secondary support | $18.00 to $20.00 | The area around the 50-day moving average. A break below this level would suggest the trend is weakening. |
| Near resistance | $31.35 to $35.00 | The 52-week high of $31.35 is the immediate resistance. Breaking above this with volume would signal trend continuation toward the analyst target of $40. |
| 50-day moving average | Approximately $22 to $25 | ALMS has traded well above the 50-day MA during the recent rally. A test of this level would be a normal pullback. |
| 200-day moving average | Approximately $12 to $16 | The 200-day MA is well below current price, reflecting the strength of the recent uptrend. |
| Momentum | RSI elevated but not extreme | The stock has rallied sharply from $3.24. Momentum is bullish but the move may be extended after such a large gain. |
| Volume | Approximately 1.34 million daily average | Volume has been elevated during the rally. Watch for volume confirmation on breakouts and volume divergence on pullbacks. |
| Volatility | Beta -0.71, low market correlation | ALMS shows low correlation with broad markets. Biotech-specific catalysts drive price action more than macro factors. |
| Invalidation | Close below $18.00, then $12.00 | A close below the 50-day MA area weakens the momentum setup. A break below the 200-day MA would challenge the long-term uptrend. |
ALMS AI trading strategy
The ALMS AI trading strategy is a rules-based framework, not personalized advice. ALMS is a clinical-stage biotech where pipeline catalysts and clinical data readouts drive price action more than traditional valuation metrics.
Look for ALMS to hold above the $24 to $26 support zone and eventually break above the $31.35 52-week high with improving volume before adding to positions.
A close below $18.00 would suggest the trend is breaking. Reduce position size if volume dries up during pullbacks.
If ALMS pulls back toward the $20 to $24 range ahead of a known catalyst such as Phase 3 data readout or regulatory milestone, monitor for signs of accumulation and consider a catalyst-based position with defined risk.
Define maximum loss per trade. Biotech stocks can gap significantly on clinical data releases. Position size should account for binary event risk.
Track envudeucitinib Phase 3 trial enrollment and data timelines, cash burn rate and quarterly financial results, analyst revisions and price targets, partnership or collaboration announcements, and competitor TYK2 developments.
Lower the rating if cash burn accelerates without clear pipeline milestones, clinical trials face enrollment delays, or safety signals emerge in the TYK2 class.
Investment research summary
Alumis develops TYK2 inhibitor therapies for autoimmune diseases, anchored by lead candidate envudeucitinib targeting plaque psoriasis and systemic lupus erythematosus.
The moat depends on clinical differentiation. The TYK2 mechanism is validated by BMS Sotyktu, but envudeucitinib needs to show superior efficacy, safety, or convenience to capture significant market share.
The thesis can fail if envudeucitinib Phase 3 data disappoints, safety signals emerge, regulatory hurdles delay approval, commercial execution falls short, or cash burn forces dilutive financing.
Professional biotech management team with industry experience. Key focus areas are clinical execution, regulatory strategy, capital management, and potential partnership or acquisition interest.
Autoimmune disease therapeutics is a large and growing market. TYK2 inhibition is an established mechanism with blockbuster potential. AI-driven drug discovery and development trends benefit the broader biotech ecosystem.
At roughly 346x TTM sales and negative TTM earnings, all forward value depends on clinical and commercial success. The stock already prices in a high probability of successful development, leaving limited room for setbacks.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALMS price | $28.31 close on July 10, 2026 | Yahoo Finance | July 12, 2026 |
| Market capitalization | $3.61 billion, verified as $28.31 x approximately 127.5 million shares | financial_rigor.py market cap verification and Yahoo Finance | July 12, 2026 |
| TTM revenue | $8.40 million | Yahoo Finance Key Statistics | July 12, 2026 |
| TTM net income | -$237.42 million | Yahoo Finance Key Statistics | July 12, 2026 |
| EPS (TTM) | -$1.78 | Yahoo Finance Summary | July 12, 2026 |
| Cash and equivalents | $522.94 million | Yahoo Finance Key Statistics | July 12, 2026 |
| Enterprise value | $3.12 billion | Yahoo Finance Key Statistics | July 12, 2026 |
| 52-week range | $3.24 to $31.35 | Yahoo Finance Summary | July 12, 2026 |
| Price/Sales (TTM) | 346.24x | Yahoo Finance Key Statistics | July 12, 2026 |
| Price/Book (MRQ) | 6.37x | Yahoo Finance Key Statistics | July 12, 2026 |
| Analyst consensus target | Average $40.10, high $55.00, low $25.00 (Chardan Capital raised to $40 on May 19) | Yahoo Finance Analyst Insights | July 12, 2026 |
| Valuation math | 346.24x P/S (TTM), negative P/E, Price/Book 6.37x from financial_rigor.py | financial_rigor.py valuation verification and Yahoo Finance | July 12, 2026 |
This ALMS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Alumis Inc. is a clinical-stage biopharmaceutical company with negative TTM earnings, no approved products, and the stock carries elevated risk.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
